Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severe prolonged sedation associated with coadministration of protease inhibitors and intravenous midazolam during bronchoscopy: a commentary.

Pharmacotherapy·2012
Same author

Sulfonamide allergy and cross-reactivity.

Current allergy and asthma reports·2007
Same author

The use of wireless laptop computers for computer-assisted learning in pharmacokinetics.

American journal of pharmaceutical education·2006
Same author

Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group.

Pharmacotherapy·2004
Same journal

Healthcare cost savings through hospital pharmacist-collaborative care in heart failure: A microsimulation study.

Journal of the American Pharmacists Association : JAPhA·2026
Same journal

Assessment of comprehensive medication management incorporating a patient-completed medical and medication history form in community practice.

Journal of the American Pharmacists Association : JAPhA·2026
Same journal

Characterizing how community pharmacy teams engage with social drivers of health (SDOH) during routine workflow: A report from the medication safety research network of Indiana (Rx-SafeNet).

Journal of the American Pharmacists Association : JAPhA·2026
Same journal

Geographic disparities in board-certified ambulatory care pharmacists in Appalachia.

Journal of the American Pharmacists Association : JAPhA·2026
Same journal

Development of consensus criteria for problematic medications in active duty service members.

Journal of the American Pharmacists Association : JAPhA·2026
Same journal

Barriers and facilitators to pharmacy-based methadone dosing and dispensing: Semi-structured interviews with pharmacists.

Journal of the American Pharmacists Association : JAPhA·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Clarifying metformin's role and risks in liver dysfunction.

Carolyn C Brackett1

  • 1College of Pharmacy, Ohio State University, 500 West 12th Ave., Columbus, OH 43210, USA. brackett.2@osu.edu

Journal of the American Pharmacists Association : Japha
|May 11, 2010
PubMed
Summary
This summary is machine-generated.

Metformin is safe for patients with liver disease and does not cause liver injury. Routine liver enzyme monitoring is not necessary before or during metformin use, except for patients with cirrhosis.

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Related Experiment Videos

Last Updated: Jun 13, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

Area of Science:

  • Endocrinology
  • Hepatology
  • Pharmacology

Background:

  • Clinicians hesitate to prescribe metformin for patients with liver disease due to concerns about hepatotoxicity and lactic acidosis.
  • Existing literature and prescribing information offer variable guidance on metformin use in liver disease.

Purpose of the Study:

  • To investigate the reasons behind clinician hesitancy in prescribing metformin for liver disease patients.
  • To determine the necessity of routine transaminase monitoring before and during metformin therapy.

Main Methods:

  • A comprehensive Medline literature search was performed from 1966 to June 2008.
  • Keywords included metformin, lactic acidosis, liver disease, hepatotoxicity, hypoxia, and predisposing factors.

Main Results:

  • Metformin does not cause or worsen liver injury and can benefit patients with nonalcoholic fatty liver disease.
  • Concerns regarding metformin-induced lactic acidosis are primarily linked to patients with cirrhosis, especially those with alcohol use and encephalopathy.
  • Routine transaminase monitoring is not supported as cirrhosis can exist with normal liver enzymes, and metformin is not intrinsically hepatotoxic.

Conclusions:

  • Metformin is generally safe and often beneficial in patients with liver disease, including nonalcoholic fatty liver disease.
  • Identifying patients with cirrhosis before initiating metformin is prudent due to increased lactic acidosis risk.
  • Withholding metformin or routine transaminase monitoring based solely on liver enzyme levels is not evidence-based.